Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0588239B2 - - Google Patents
[go: Go Back, main page]

JPH0588239B2 - - Google Patents

Info

Publication number
JPH0588239B2
JPH0588239B2 JP5752185A JP5752185A JPH0588239B2 JP H0588239 B2 JPH0588239 B2 JP H0588239B2 JP 5752185 A JP5752185 A JP 5752185A JP 5752185 A JP5752185 A JP 5752185A JP H0588239 B2 JPH0588239 B2 JP H0588239B2
Authority
JP
Japan
Prior art keywords
apc
isopropyl alcohol
hydrobromic acid
present
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP5752185A
Other languages
Japanese (ja)
Other versions
JPS61215396A (en
Inventor
Sadakatsu Shimada
Toshiaki Tojo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP5752185A priority Critical patent/JPS61215396A/en
Publication of JPS61215396A publication Critical patent/JPS61215396A/en
Publication of JPH0588239B2 publication Critical patent/JPH0588239B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Cephalosporin Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

産業上の利用分野 本発明は次式(1) Industrial applications The present invention is based on the following formula (1)

【化】 (式中、mは1または2の数を示す) で表わされる、セフアロスポリン系抗生物質の中
間体として有用な新規な7−アミノ−3−ピリジ
ニウムメチル−セフエム誘導体に関する。 従来技術 従来、(6R,7R)−7−アミノ−3−(1−ピ
リジニウム)メチル−3−セフエム−4−カルボ
キシレート(以下APCと表わす)は7位のアミ
ノ基の保護基を化学的方法あるいは生物学的方法
により除去して製造されて来たが、これまでの方
法では含量の比較的低い反応液より安定性に優れ
た高純度化合物を収率良く単離することは困難で
あつた。そこで本発明者は本化合物の安定性に優
れた高純度塩の高収率な単離法を見い出すべく鋭
意検討した結果本発明を完成した。 発明の目的 本発明は安定性に優れた高純度結晶性APC・
臭化水素酸塩・水和物を提供するものである。 本発明によれば接種等の特別な操作を必要とせ
ず、難溶性の高純度な結晶性の塩を容易に単離す
ることが出来る。 問題を解決するための手段 本発明のAPC・臭化水素酸塩・水和物は次の
いずれの方法によつても製造される。 (A) APCを含む中性溶液に臭化水素酸を加えた
後、イソプロピルアルコール等の水と混じり合
う有機溶媒を加える。 (B) APCとハロゲン化水素酸を含む水溶液に臭
化水素酸を加え次いでイソプロピルアルコール
を加える。 (A)の方法をさらに詳しく説明する。 使用される臭化水素酸は特に限定されず市販品
をそのまま用いる事が可能であり、水にて希釈し
て使用しても良い。臭化水素酸は、APCに対し、
2〜5倍モル使用すれば一臭化水素酸塩・一水和
物が、10倍モル以上使用すれば二臭化水素酸塩・
二水和物がそれぞれ選択的に生成する。使用する
有機溶媒はイソプロピルアルコール、n−プロピ
ルアルコール等のアルコール類、テトラヒドロフ
ラン等のエーテル類、アセトニトリル等のニトリ
ル類、アセトン等のケトン類など水と混じり合う
有機溶媒なら使用可能であり、好適にはイソプロ
ピルアルコールである。 次に(B)の方法をさらに詳しく説明する。 (A)の方法で得られる一臭化水素酸塩または
APC塩酸塩類を水に溶解した溶液、あるいは
APCの上記ハロゲン化水素酸、酸性溶液に臭化
水素酸を2〜20倍モル、好ましくは5〜15倍モル
加え、続いてイソプロピルアルコールを加えると
APC・二臭化水素酸塩・二水和物が析出する。
ここで使用する臭化水素酸も(A)法と同様、市販品
で十分であり、そのままあるいは水にて希釈して
使用する事が出来る。 (A)法及び(B)法で使用される有機溶媒、例えばイ
ソプロピルアルコールの使用量は特に限定され
ず、一般には使用水溶液の10〜20倍が好適であ
る。また、(A)法及び(B)法にて使用されるAPCの
水溶液の濃度は特に限定されないが、一般には3
%〜30%が好適である。これらの方法は臭化水素
酸を加えた時点で、あるいは有機溶媒を加える事
により速やかに晶析が起こる。(A)法及び(B)法の操
作は室温で行なえば良いが、5℃前後に冷しても
良い。 本発明にて得られる化合物はいずれも水に対す
る溶解度が小さいという特徴を有する。たとえば
15%のAPC塩酸塩水溶液に臭化水素酸10倍モル
を加えればそれだけで難溶性の二臭化水素酸塩・
二水和物が析出する。これにイソプロピルアルコ
ールを加えるとさらに高収率(90%以上)で二臭
化水素酸塩・二水和物が得られるので、希薄な水
溶液より容易にAPCを単離することが出来る。
このため本発明は例えば醗酵液等の希薄水溶液の
回収精製に利用出来るという有用性をも有する。 本発明で得られる化合物類は安定な化合物であ
り、封管中60℃にて一週間放置してもほとんど分
解しない。 本発明により得られる化合物はセフアロスポリ
ン系抗生物質の製造中間体として有用であり、例
えば、これに式
The present invention relates to a novel 7-amino-3-pyridinium methyl-cephem derivative useful as an intermediate for cephalosporin antibiotics, represented by the formula: (wherein m represents a number of 1 or 2). Prior art Conventionally, (6R,7R)-7-amino-3-(1-pyridinium)methyl-3-cephem-4-carboxylate (hereinafter referred to as APC) was prepared by chemically converting the protecting group of the amino group at the 7-position. Alternatively, they have been produced by removing them using biological methods, but with conventional methods it has been difficult to isolate high-purity compounds with good yields that are more stable than the reaction solution with a relatively low content. . Therefore, the present inventor completed the present invention as a result of intensive studies to find a high-yield method for isolating a highly stable and highly pure salt of the present compound. Purpose of the invention The present invention is a highly stable crystalline APC.
It provides hydrobromide hydrate. According to the present invention, a hardly soluble, highly pure crystalline salt can be easily isolated without the need for special operations such as inoculation. Means for Solving the Problems The APC/hydrobromide/hydrate of the present invention can be produced by any of the following methods. (A) Add hydrobromic acid to a neutral solution containing APC, then add a water-miscible organic solvent such as isopropyl alcohol. (B) Hydrobromic acid is added to an aqueous solution containing APC and hydrohalic acid, and then isopropyl alcohol is added. Method (A) will be explained in more detail. The hydrobromic acid used is not particularly limited, and commercially available products can be used as they are, or may be used after being diluted with water. Hydrobromic acid, for APC,
If 2 to 5 times the mole is used, monohydrobromide/monohydrate will be produced, and if 10 times the mole or more is used, dihydrobromide/monohydrate will be produced.
Each dihydrate is selectively produced. The organic solvent to be used may be any organic solvent that is miscible with water, such as alcohols such as isopropyl alcohol and n-propyl alcohol, ethers such as tetrahydrofuran, nitrites such as acetonitrile, and ketones such as acetone. It is isopropyl alcohol. Next, method (B) will be explained in more detail. Monohydrobromide obtained by method (A) or
A solution of APC hydrochloride dissolved in water, or
Adding 2 to 20 times the mole of hydrobromic acid, preferably 5 to 15 times the mole, to the above-mentioned hydrohalic acid and acidic solution of APC, and then adding isopropyl alcohol.
APC/dihydrobromide/dihydrate precipitates.
Similar to method (A), the hydrobromic acid used here is a commercially available product and can be used as it is or diluted with water. The amount of the organic solvent used in methods (A) and (B), such as isopropyl alcohol, is not particularly limited, and is generally preferably 10 to 20 times the amount of the aqueous solution used. In addition, the concentration of the APC aqueous solution used in methods (A) and (B) is not particularly limited, but is generally 3.
% to 30% is suitable. In these methods, crystallization occurs immediately upon adding hydrobromic acid or by adding an organic solvent. The operations of methods (A) and (B) may be carried out at room temperature, but may also be cooled to around 5°C. All of the compounds obtained in the present invention are characterized by low solubility in water. for example
Adding 10 times the mole of hydrobromic acid to a 15% aqueous solution of APC hydrochloride produces a sparingly soluble dihydrobromide.
Dihydrate precipitates out. When isopropyl alcohol is added to this, dihydrobromide dihydrate can be obtained in even higher yield (over 90%), so APC can be isolated more easily than in a dilute aqueous solution.
Therefore, the present invention is also useful in that it can be used, for example, to collect and purify dilute aqueous solutions such as fermentation liquids. The compounds obtained in the present invention are stable compounds, and hardly decompose even if left in a sealed tube at 60°C for one week. The compounds obtained according to the present invention are useful as intermediates for the production of cephalosporin antibiotics.

【式】 (式中、R1及びR2は同一または異なり、水素
原子あるいは保護基を表わし、R3は水素原子あ
るいはアルカリ金属を表わす)で表わされる化合
物もしくはそれに相当するアシル化剤と反応さ
せ、次いで必要なら保護基を除去することにより
目的の化合物が製造される。 以下実施例及び参考例をもつて本発明を説明す
る。 実施例 1 (6R,7R)−7−アミノ−3−(1−ピリジニ
ウム)メチル−3−セフエム−4−カルボキシレ
ート(APC)18.7mmolを含む水溶液200mlに47.5
%臭化水素酸8.6mlを加え、続いてイソプロピル
アルコール2.0を加える。そのまま室温で30分
攪拌後、析出結晶を濾取し、イソプロピルアルコ
ール100mlにて洗浄する。結晶を乾燥し、APC・
一臭化水素酸塩・一水和物6.79g(93%)を得
た。1 H−NMR(in D2O) δ:(PPM) 3.54(2H、ABq、J=18.0Hz、セフエム環 2位
のCH2) 5.24(1H、d、J=5.0Hz、セフエム環 6位の
H) 5.36(1H、d、J=5.0Hz、セフエム環 7位の
H) 5.53(2H、ABq、J=15.0Hz、セフエム環 3位
のCH2) 8.16(2H、t、J=7.0Hz、ピリジン 3,5位
のH) 8.65(1H、t、J=7.0Hz、ピリジン 4位のH) 9.01(2H、d、J=7.0Hz、ピリジン 2,6位
のH) IR(KBr)νcm-1:3400,1795,1610,1480,
1395,1335,1150,1050 元素分析値 C13H16N3O4SBr 実測値 C40.05, H4.13, N10.78,
Br20.63 計算値 C40.01, H4.13, N10.77,
Br20.48 融点 160〜170℃(着色分解) 示差熱分析によれば本品は150〜165℃に吸熱ピ
ークを示し170〜175℃で発熱ピークを示す。 本品のニツケルをフイルターとするλ=1.542
Åの銅X線を用いた粉末X線回折は以下の表1の
特性を示す。(ただし表1中Sは強、Mは中等度、
Wは弱、Vは非常にそしてDは拡散をそれぞれ意
味する)
[Formula] (wherein R 1 and R 2 are the same or different and represent a hydrogen atom or a protecting group, and R 3 represents a hydrogen atom or an alkali metal) or an acylating agent equivalent thereto. The desired compound is then prepared by removing the protecting group if necessary. The present invention will be explained below with reference to Examples and Reference Examples. Example 1 (6R,7R)-7-Amino-3-(1-pyridinium)methyl-3-cephem-4-carboxylate (APC) 47.5 to 200 ml of an aqueous solution containing 18.7 mmol
Add 8.6 ml of % hydrobromic acid followed by 2.0 ml of isopropyl alcohol. After stirring for 30 minutes at room temperature, the precipitated crystals are collected by filtration and washed with 100 ml of isopropyl alcohol. Dry the crystals, APC・
6.79 g (93%) of monohydrobromide monohydrate was obtained. 1 H-NMR (in D 2 O) δ: (PPM) 3.54 (2H, ABq, J = 18.0Hz, CH 2 at the 2nd position of the Cephem ring) 5.24 (1H, d, J = 5.0Hz, the 6th position of the Cephem ring H) 5.36 (1H, d, J = 5.0Hz, H at the 7th position of the Cefem ring) 5.53 (2H, ABq, J = 15.0Hz, CH 2 at the 3rd position of the Cefem ring) 8.16 (2H, t, J = 7.0Hz, Pyridine H at positions 3 and 5) 8.65 (1H, t, J = 7.0Hz, H at 4th position of pyridine) 9.01 (2H, d, J = 7.0Hz, H at positions 2 and 6 of pyridine) IR (KBr) νcm - 1 : 3400, 1795, 1610, 1480,
1395, 1335, 1150, 1050 Elemental analysis value C 13 H 16 N 3 O 4 SBr Actual measurement value C40.05, H4.13, N10.78,
Br20.63 Calculated value C40.01, H4.13, N10.77,
Br20.48 Melting point 160-170℃ (color decomposition) According to differential thermal analysis, this product shows an endothermic peak at 150-165℃ and an exothermic peak at 170-175℃. λ = 1.542 using this product's nickel filter
Powder X-ray diffraction using copper X-rays of Å shows the properties shown in Table 1 below. (However, in Table 1, S is strong, M is moderate,
W means weak, V means very much, and D means diffused.)

【表】【table】

【表】 実施例 2 APC・一臭化水素酸塩・一水和物0.977gに水
5ml及び47.5%臭化水素酸5mlを加え続いてイソ
プロピルアルコール100mlを加える。1時間氷冷
後、析出晶を濾取し、イソプロピルアルコール
30mlにて洗浄する。結晶を減圧下で乾燥後、飽
和食塩水と共にデシケーター中に4時間放置し、
APC・二臭化水素酸塩・二水和物0.963g(79%)
を得た。1 H−NMR(in D2O) δ:(PPM) 3.61(2H、ABq、J=18.0Hz、セフエム環 2位
のCH2) 5.29(1H、d、J=5.0Hz、セフエム環 6位の
H) 5.43(1H、d、J=5.0Hz、セフエム環 7位の
H) 5.65(2H、ABq、J=15.0Hz、セフエム環 3位
のCH2) 8.18(2H、t、J=7.0Hz、ピリジン 3,5位
のH) 8.68(1H、t、J=7.0Hz、ピリジン 4位のH) 9.04(2H、d、J=7.0Hz、ピリジン 2,6位
のH) IR(KBr)νcm-1:3425,2950,1790,1700,
1625,1495,1475 元素分析値 C13H19N3O5SBr2 実測値 C32.43, H3.80, N8.73, Br32.73 計測値 C31.92, H3.91, N8.59, Br32.67 融点 150〜170℃(分解) 示差熱分析によれば本品は50〜90℃および130
〜150℃に二つの吸熱ピークを示し、160〜165℃
で発熱ピークを示す。 本品のニツケルをフイルターとするλ=1.542
Åの銅X線を用いた粉末X線回折は以下の表2の
特性を示す。(表中S、M、W、V、Dはそれぞ
れ表1のそれと同一の意味を示す)
[Table] Example 2 Add water to 0.977g of APC/hydrobromide/monohydrate
Add 5 ml and 5 ml of 47.5% hydrobromic acid followed by 100 ml of isopropyl alcohol. After cooling on ice for 1 hour, the precipitated crystals were collected by filtration and diluted with isopropyl alcohol.
Wash with 30ml. After drying the crystals under reduced pressure, they were left in a desiccator with saturated saline for 4 hours.
APC/dihydrobromide/dihydrate 0.963g (79%)
I got it. 1 H-NMR (in D 2 O) δ: (PPM) 3.61 (2H, ABq, J = 18.0Hz, CH 2 at the 2nd position of the Cephem ring) 5.29 (1H, d, J = 5.0Hz, the 6th position of the Cephem ring H) 5.43 (1H, d, J = 5.0Hz, H at the 7th position of the Cefem ring) 5.65 (2H, ABq, J = 15.0Hz, CH 2 at the 3rd position of the Cefem ring) 8.18 (2H, t, J = 7.0Hz, Pyridine H at positions 3 and 5) 8.68 (1H, t, J = 7.0Hz, H at position 4 of pyridine) 9.04 (2H, d, J = 7.0Hz, H at positions 2 and 6 of pyridine) IR (KBr) νcm - 1 : 3425, 2950, 1790, 1700,
1625, 1495, 1475 Elemental analysis value C 13 H 19 N 3 O 5 SBr 2 Actual value C32.43, H3.80, N8.73, Br32.73 Measured value C31.92, H3.91, N8.59, Br32 .67 Melting point: 150-170°C (decomposition) According to differential thermal analysis, this product has a melting point of 50-90°C and 130°C.
Shows two endothermic peaks at ~150℃, 160-165℃
shows an exothermic peak. λ = 1.542 using this product's nickel filter
Powder X-ray diffraction using Å copper X-rays shows the properties shown in Table 2 below. (S, M, W, V, and D in the table each have the same meaning as in Table 1)

【表】【table】

【表】 実施例 3 APC・二塩酸塩3.56gを水9mlに溶解し、47.5%
臭化水素酸11.4mlを加える。結晶が析出した所へ
さらにイソプロピルアルコール200mlを加え氷冷
下1時間攪拌する。析出晶を減圧下乾燥し、飽和
食塩水と共にデシケーター中に放置し、APC・
二臭化水素酸塩・二水和物4.29g(90%)を得た。 本品は実施例2で得た化合物と一致した。 実施例 4 実施例1のイソプロピルアルコールの代わりに
アセトンを使用し同様の操作を行ないAPC・一
臭化水素酸塩・一水和物を得た。
[Table] Example 3 Dissolve 3.56g of APC dihydrochloride in 9ml of water, 47.5%
Add 11.4 ml of hydrobromic acid. Add another 200 ml of isopropyl alcohol to the area where crystals have precipitated, and stir for 1 hour under ice cooling. The precipitated crystals were dried under reduced pressure, left in a desiccator with saturated saline, and APC・
4.29 g (90%) of dihydrobromide dihydrate was obtained. This product was consistent with the compound obtained in Example 2. Example 4 The same operation as in Example 1 was carried out using acetone instead of isopropyl alcohol to obtain APC monohydrobromide monohydrate.

Claims (1)

【特許請求の範囲】 1 式 【化】 (式中、mは1または2の数を示す) で表わされる7−アミノ−3−ピリジニウムメチ
ル−セフエム誘導体。
[Claims] 1. A 7-amino-3-pyridinium methyl-cephem derivative represented by the formula: (wherein m represents a number of 1 or 2).
JP5752185A 1985-03-20 1985-03-20 7-amino-3-pyridinium methyl-cephem derivative Granted JPS61215396A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5752185A JPS61215396A (en) 1985-03-20 1985-03-20 7-amino-3-pyridinium methyl-cephem derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5752185A JPS61215396A (en) 1985-03-20 1985-03-20 7-amino-3-pyridinium methyl-cephem derivative

Publications (2)

Publication Number Publication Date
JPS61215396A JPS61215396A (en) 1986-09-25
JPH0588239B2 true JPH0588239B2 (en) 1993-12-21

Family

ID=13058036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5752185A Granted JPS61215396A (en) 1985-03-20 1985-03-20 7-amino-3-pyridinium methyl-cephem derivative

Country Status (1)

Country Link
JP (1) JPS61215396A (en)

Also Published As

Publication number Publication date
JPS61215396A (en) 1986-09-25

Similar Documents

Publication Publication Date Title
KR100442717B1 (en) Crystalline amine salt of cefdinir
JP2012236841A (en) Crystal modification b of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
GB2213819A (en) Salts of 7 - [alpha-(2 aminothiazol-4-yl)-alpha-(Z)-methoxyimino-acetamido]-3-[(1-methyl-1-pyrrolidino) methyl]-3-cephem-4-carboxylate
EP1848724A2 (en) Process for the preparation of cefdinir
US4146710A (en) Solid cephalosporin salt
DK148022B (en) PROCEDURE FOR PREPARING THE ALFA FORM OF CRYSTALLINE SODIUM-O-FORMYL-CEFAMANDOL
EP1618114A2 (en) Processes for the preparations of cefepime
CA1236089A (en) Ceftazidime
JP2003513983A (en) Method for producing high-purity cefpodoxime proxetil
JPH0588239B2 (en)
KR870000327B1 (en) Process for preparing crystalline 7-(r)-amino-3-(1-pyridiniummethyl)-ceph-3-em-4-carboxylate
US4035361A (en) Bis-trimethylsilyl cefamandole and process therefor
CA1144558A (en) Process for making sodium hydrogen divalproate
JP2008520596A (en) Crystalline form of cefdinir ammonium salt as an intermediate for the preparation of pure cefdinir
JPWO2004085443A1 (en) 7- [2- (2-Aminothiazol-4-yl) -2-hydroxyiminoacetamido-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) new crystal and process for producing the same
CN101111498B (en) Cefcapene pivoxil methanesulfonate
JP2568245B2 (en) 3-Cephem derivative borofluoride / borofluoride
KR830001415B1 (en) Process for preparing cephalosporin derivatives
JP2662414B2 (en) Thiazole derivatives
EP0321562B1 (en) Crystalline cephalosporin compounds, process for their preparation, and intermediates for their preparation
KR930007816B1 (en) New Preparation Method of Cefem Compound
KR860001087B1 (en) Process for preparing cephalosporanic acid derivatives
KR970004047B1 (en) Novel Processes for Sepem Compound
JP2661810B2 (en) Method for producing 7-amino-3-chloromethyl-3-cephem derivative
JPS63211280A (en) Production of 2-(4-thiazolyl)benzimidazole